NIH team touts experimental Epstein-Barr virus vaccine; Madison Vaccines pairs its prostate cancer jab with Keytruda;

> A nanoparticle-based experimental vaccine, developed by a team from the National Institute of Allergy and Infectious Diseases and its collaborators, was shown to induce antibodies against Epstein-Barr virus in mice and primates. Release

> Madison Vaccines initiated a combination trial of its lead prostate cancer vaccine candidate paired with Merck's ($MRK) checkpoint inhibitor Keytruda. Release

> Emergent BioSolutions ($EBS) received a $44 million contract option for the supply of its Vigiv--which treats complications due to smallpox vaccination--to the national stockpile. Release

Suggested Articles

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Sanofi's cost cuts are adding up, execs said in an update Wednesday. The company has trimmed nearly €1 billion in annual expenses so far in 2020.

Shingrix sales in the second quarter plummeted by half from first-quarter levels, and recovery of vaccination rates remains slow amid the pandemic.